Great to speak yesterday at the ACP Florida Chapter meeting and spend time with my uncle, Dr. Sergio Perez Sr., an outstanding internist! Grateful to Dr. Mario Madruga and the organizers for the invitation.
1
137
Excellent talk by @MichaelDJain at #SOHO2026 on CAR T and BsA toxicities prevention and management
Some days remind you why we do this. Our patients’ courage never ceases to inspire. Honored to give a survivor medal to a brave patient—2 years post-ASCT for MCL (image posted with permission) @BaptistHealthSF
5
162
Very productive @FLASCO_ORG Business of Oncology Summit yesterday. It was a pleasure to participate alongside such an outstanding faculty group.
Don’t miss the education sessions at the Spring Congress—now underway.
Ariel Perez retweeted
Registration is open for the Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies 🗓️ Mar 6–7, 2026 bapth.lt/ImmunoSummit
#HemeOnc #CART #AML #Lymphoma #MultipleMyeloma
Great MRD in AML session #Tandem26 Loved the practical insights from Dr Nadia Bambace and @SagheerTiba Lots of takeaways for real world practice. Privileged to work with them @BaptistHealthSF
Ariel Perez retweeted
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide. Co-authored by @DholariaMD.
Read the full article. brnw.ch/21wYHmR
Phase 1b double-dose axi-cel presented by Caroline Lee (Stanford). High response rates with axi-cel 2, greater CAR AUC with less exhausted phenotypes and low added toxicity. Excellent talk!
1
2
218
Excited to be in Orlando for #ASH25. A special thanks to the organizers for the birthday gift. My collection of heme socks continues to grow!
1
3
152
Ariel Perez retweeted
CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, 1-yr OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncol…
Ariel Perez retweeted
An honor and a privilege to have been part of this collaborative study across frontline DLBCL trials.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L
Read the full article. brnw.ch/21wV02q
#lymsm
Ariel Perez retweeted
But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs!
v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500...
Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!
Ariel Perez retweeted
I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇
onlinelibrary.wiley.com/shar…
🔑 findings:
💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes.
💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%).
💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity.
❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL
🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X.
Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅
👉Please share with your network if you learnt something with this post 🙏
#HemOnc #MedEd #lymphomasm #CARTcelltherapy
I am thrilled to announce my promotion to Medical Director of Cellular Therapy. It has been an amazing 4 years since I joined @BaptistHealthSF. I am looking forward to continue developing the Miami Cancer Institute adoptive cell therapy program with our amazing team and leaders.
2
12
746
Ariel Perez retweeted
Replying to @BLLPHD
Finally, awake after a long REMS slumber!!! @ASTCT
astctjournal.org/article/S26…
Ariel Perez retweeted
Using CARTs for first relapse in myeloma.
#mmsm
open.substack.com/pub/rafael…
Ariel Perez retweeted
Thank you to @MichaelDJain from @MoffittNews for helping us create this guide and sharing his insights on life after lymphoma. #lymsm
Ariel Perez retweeted
Join Dr Ariel Perez from @MiamiCancerInst in San Juan for a weekend that brings the biggest cancer updates from #ASCO25 straight to Puerto Rico!
Don't wait!
👉 Register for free today: totalhealthoncology.com/upco…
#ASCODirect25 #CME #MedicalEducation #Oncology @app1279
Ariel Perez retweeted
A study led by Dr. Malpica of our Rare Lymphoma Section found adult T-cell leukemia or lymphoma and extranodal NKT-cell lymphoma are more prevalent among Latin Americans (LA), calling for greater LA participation in global T cell lymphoma research. tinyurl.com/PTCL-Latin

































